NovaBay Pharmaceuticals, Inc. (NBY)

NovaBay Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	-	10.46	14.4	10.2
Revenue Growth (YoY)	-	-	-27.42%	41.16%	2.72%
Cost of Revenue	-	-	4.37	6.62	3.69
Gross Profit	-	-	6.08	7.78	6.52
Selling, General & Admin	7.59	7.38	10.15	15.29	15.33
Research & Development	-	-	0.03	0.17	0.04
Other Operating Expenses	0.85	-	-	6.74	-
Total Operating Expenses	8.44	7.38	10.19	22.2	15.38
Operating Income	-8.44	-7.38	-4.1	-14.42	-8.86
Interest Expense	-0.28	-0.9	-1.69	-	-
Other Non-Operating Income (Expense)	-24.51	-0.47	-0.35	3.81	3.04
Total Non-Operating Income (Expense)	-24.78	-1.37	-2.04	3.81	3.04
Pretax Income	-33.22	-8.75	-6.15	-10.61	-5.82
Net Income	-22.14	-8.61	-16.97	-16.27	-6.56
Net Income Attributable to Preferred Dividends	-	1.39	7.06	-5.66	-0.74
Earnings From Discontinued Operations	11.08	1.53	-3.5	-	-
Net Income to Common	-22.14	-8.61	-16.97	-16.27	-6.56
Shares Outstanding (Basic)	6	1	0	0	0
Shares Outstanding (Diluted)	6	1	0	0	0
Shares Change (YoY)	757.14%	2729.17%	160.87%	29.11%	24.43%
EPS (Basic)	-3.80	-12.68	-695.70	-1767.50	-920.50
EPS (Diluted)	-3.80	-12.68	-695.70	-1767.50	-920.50
Shares Outstanding	25.22	0.98	0.06	0.01	0.01
Free Cash Flow	2.7	-4.2	-4.15	-6.77	-9.24
Free Cash Flow Per Share	0.46	-6.18	-172.92	-735.43	-1297.27
Gross Margin	-	-	58.19%	54.02%	63.85%
Operating Margin	-	-	-39.23%	-100.09%	-86.85%
Profit Margin	-	-	-58.78%	-73.65%	-57.08%
FCF Margin	-	-	-39.69%	-46.97%	-90.59%
EBITDA	-8.44	-7.38	-4.05	-13.93	-8.74
EBITDA Margin	-	-	-38.75%	-96.74%	-85.68%
EBIT	-8.44	-7.38	-4.1	-14.42	-8.86
EBIT Margin	-	-	-39.23%	-100.09%	-86.85%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q